Federated Hermes Inc. Has $6.28 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Federated Hermes Inc. lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 77.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 80,713 shares of the medical device company’s stock after selling 282,160 shares during the quarter. Federated Hermes Inc.’s holdings in DexCom were worth $6,277,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Versant Capital Management Inc bought a new position in DexCom in the fourth quarter worth $25,000. Private Trust Co. NA raised its stake in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC boosted its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new stake in DexCom in the fourth quarter valued at about $38,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

Shares of DexCom stock opened at $66.14 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a 50 day simple moving average of $76.92 and a 200 day simple moving average of $76.62. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $139.24. The firm has a market cap of $25.93 billion, a P/E ratio of 46.25, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of analyst reports. Canaccord Genuity Group raised their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Cfra Research upgraded DexCom to a “hold” rating in a research report on Friday, March 21st. Morgan Stanley lifted their price objective on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Finally, Citigroup upped their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $99.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.